SAN FRANCISCO, Aug. 26, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based
genetic medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases, today
announced that it will participate in the following investor
conferences in September:
Citi's 14th Annual Biotech Conference
Matthew R. Patterson, Chariman and Chief
Executive Officer
Format: 1x1 Investor Meetings
Wednesday, September 4, 2019 -
Thursday, September 5, 2019
Boston, Massachusetts
Morgan Stanley 17th Annual Global Healthcare
Conference
Natalie Holles,
President and Chief Operating Officer
Format: Fireside Chat
Monday, September 9, 2019, at
11:05 am ET
New York, New York
To access the live webcast of the Morgan Stanley fireside chat,
please visit the Events & Presentations page within the
Investors + Media section of the Audentes website. Following
the conference, a replay of the live webcast will be available on
the Audentes website for approximately 30 days.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases.
We are leveraging our AAV gene therapy technology platform and
proprietary manufacturing expertise to develop programs across
three modalities: gene replacement, vectorized exon skipping, and
vectorized RNA knockdown. Our product candidates are showing
promising therapeutic profiles in clinical and preclinical studies
across a range of neuromuscular diseases. Audentes is a
focused, experienced and passionate team driven by the goal of
improving the lives of patients.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Sarah Spencer
415.957.2020
sspencer@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-upcoming-investor-conferences-300905998.html
SOURCE Audentes Therapeutics, Inc.